Skip to main content
Premium Trial:

Request an Annual Quote

Signal Genetics Signs Reimbursement Agreement with America's Choice Provider Network

NEW YORK (GenomeWeb) – Signal Genetics today announced that is has signed an agreement to make its MyPRS assay available to 22 million patients covered by America's Choice Provider Network (ACPN).

MyPRS is microarray-based prognostic test for multiple myeloma and stratifies patients into molecular subtypes and into high- and low-risk categories using gene expression profiling.

"[W]e expect increased reimbursement support for our assay through agreements such as this to have a positive impact on our revenue generation over the long term," Signal Genetics CFO Tamara Seymour said in a statement. "As part of our overall growth strategy, we will continue to seek out these types of opportunities to ensure stable reimbursement as we work to make MyPRS available for physicians and patients across the US."

In April, Carlsbad, California-based Signal Genetics received accreditation from the College of American Pathologists for its laboratory in Little Rock, Arkansas.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.